Strategists and investors are confident that the new administration will fuel the state of mergers and acquisitions in the ...

In a recent study published in Nature Cancer, researchers explore treatment resistance and relapse in T-cell acute ...

BALDWIN PARK, CA, USA I2, 2024 I StemCyte Inc., a wholly owned subsidiary of StemCyte International Ltd., announced today that the U.S. Food and ...

Campus Chemical Instrument Center, Mass Spectrometry & Proteomics Facility, The Ohio State University, Columbus, USA ...

ALL, certain drugs work for some patients who relapse, but these drugs are not effective for all patients who relapse.

Using adeno-associated viruses (AAVs), scientists mapped neural circuits in frogs, tracing changes during metamorphosis. This ...

Researchers have discovered the underlying biology that identifies a subset of patients with acute lymphoblastic leukemia who ...

The approval is supported by data from the COBLT study, FDA dockets and public information, and an observational database.

S.BIOMEDICS reported that TED-A9, an investigational cell therapy for Parkinson's disease, showed positive data during the ...

Prime Medicine's strategic collaboration with Bristol Myers provided $55 million in cash upfront. Read why I upgrade PRME stock from hold to buy.

Secretome Therapeutics Inc. has closed a $20.4 million round of financing to support its development of therapies derived from neonatal cardiac progenitor cells.